← Back to screener

CytomX Therapeutics, Inc. CTMX

Rank #1696 · Nasdaq · $0.5B market cap
Audited by Ernst & Young LLP, no going-concern flag in the latest filing.
Score
44.1
P/E
16.0
P/B
-10.74
ROE
-67.2%
Op. Margin
18.1%
Debt Ratio
-255%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆
Average

P/E 16.0x, P/B -10.74x. Ranks in the top 59% of the universe.

Profitability ★★☆☆☆
Average

ROE -67.2%. Ranks in the top 56% of the universe.

Safety ★★★★★
Excellent

Debt ratio -255%. Ranks in the top 5% of the universe. Under 100% is generally considered a safe level.

Growth ★★★★★
Excellent

Revenue growth of 36.4% year over year. Ranks in the top 9% of the universe.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2015$0.0B$-0.0B$-0.0B$-0.0B-1684.2-288
2016$0.0B$-0.0B$-0.0B$-0.0B-586.3-161
2017$0.0B$-0.0B$-0.0B$-0.1B-430.5-154
2018$0.0B$-0.1B$-0.1B$0.1B-396.1260
2019$0.1B$-0.0B$-0.0B$0.1B-64.6416
2020$0.1B$-0.1B$-0.1B$0.1B-130.9415
2021$0.1B$-0.1B$-0.1B$0.1B-192.9236
2022$0.0B$-0.1B$-0.1B$-0.0B-311.0-4372
2023$0.1B$-0.1B$-0.1B$-0.0B-190.6-75521
2024$0.1B$-0.0B$-0.0B$-0.1B-6.4-291
2025$0.1B$0.0B$0.0B$-0.0B18.1-255

← See the full screener